Levofloxacin-related seizure activity in a patient with Alzheimer's disease: Assessment of potential risk factors [7]

Journal of Clinical Psychopharmacology

Volumn 25, Issue 3, 2005, Pages 287-288

  Bird, Steven B ^a   Orr, Patrick G ^b   Mazzola, Jennifer L ^b   Brush, D Eric ^a   Boyer, Edward W ^a,c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CITALOPRAM; CREATININE; DONEPEZIL; DOXAZOSIN; FOLIC ACID; GABAPENTIN; LEVOFLOXACIN; RANITIDINE; VALPROATE SEMISODIUM;

AGED; ALZHEIMER DISEASE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CREATININE CLEARANCE; DRUG WITHDRAWAL; HUMAN; KIDNEY FAILURE; LABORATORY TEST; LETTER; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEIZURE; URINARY TRACT INFECTION;

AGED; ALZHEIMER DISEASE; HUMANS; MALE; OFLOXACIN; RISK FACTORS; SEIZURES; UROLOGIC DISEASES;

EID: 18844448753     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000162811.15066.8e     Document Type: Letter

References (20)

1. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis. 1999;28:352-364.
2. Ball P, Mandell L, Niki Y, et al. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf. 1999;21:401-421.
3. Yagawa K. Latest industry information on the safety profile of levofloxacin in Japan. Chemotherapy. 2001;47(suppl 3):38-43.
4. Martin SJ, Meyer JM, Chuck SK, et al. Levofloxacin and sparfloxacin: new quinolones antibiotics. Ann Pharmacother. 1998;32:320-336.
5. Williams PD, Helton DR. The proconvulsive activity of quinolone antibiotics in an animal model. Toxicol Lett. 1991;58:23-28.
6. Akahane K, Sekiguchi M, Une T, et al. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with γ-aminobutyric acid receptor sites. Antimicrob Agents Chemother. 1989;33:1704-1708.
7. Tsuji A, Sato H, Kume Y, et al. Inhibitory effects of quinolone antibacterial agents on γ-aminobutyric acid binding to receptor sites in rat brain membranes. Antimicrob Agents Chemother. 1988;32:190-194.
8. de Sarro A, de Sarro G. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr Med Chem. 2001;8:371-384.
9. Schmuck G, Schurmann A, Schluter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother. 1998;42:1831-1836.
10. Levaquin (levofloxacin) [product information]. Raritan, NJ: Ortho-McNeil Pharmaceutical Inc; November 2003.
11. Babic T, Zurak N. Convulsions induced by donepezil (letter). J Neurol Neurosurg Psychiatry. 1999;66:410.
12. Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol. 2000;57:94-99.
13. Aricept (donepezil) [product information]. Teaneck, NJ: Eisai Inc; August 2002.
14. de Belleroche J, Gardiner IM. Inhibitory effect of 1,2,3,4-tetrahydro-9- aminoacridine on the depolarization-induced release of GABA from cerebral cortex. Br J Pharmacol. 1998;94:1017-1019.
15. Kushner JM, Peckman HJ, Snyder CR. Seizures associated with fluoroquinolones. Ann Pharmacother. 2001;35:1194-1198.
16. Christ W. Central nervous system toxicity of quinolones: human and animal findings. J Antimicrob Chemother. 1990;26:219-225.
17. 35S]t-butylbicyclophosphorothionate binding. Mol Pharmacol. 1993;43:795-800.
18. Milne RJ, Goa KL. Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991;41:450-477.
19. Depakote (valproic acid) [product information]. North Chicago, IL: Abbot Laboratories; 1998.
20. Neurontin (gabapentin) [product information]. Vega Baja, PR: Parke Davis Pharmaceuticals Ltd; May 2002.